Arvinas Inc. (ARVN) and Pfizer (PFE) Announce PROTAC Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breas

Go back to Arvinas Inc. (ARVN) and Pfizer (PFE) Announce PROTAC Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breas
(NASDAQ: ARVN) Delayed: 9.41 +0.09 (0.97%)
Previous Close $9.32    52 Week High
Open $9.27    52 Week Low
Day High $9.43    P/E N/A 
Day Low $9.15    EPS
Volume 187,922       

Pfizer Inc. (NYSE: PFE) Delayed: 28.13 -0.17 (0.6%)
Previous Close $28.30    52 Week High $37.39 
Open $27.97    52 Week Low $28.25 
Day High $28.17    P/E 17.05 
Day Low $27.83    EPS $1.65 
Volume 11,815,622